NO20092274L - Ansamycinformuleringer og fremgangsmater for anvendelse derav - Google Patents

Ansamycinformuleringer og fremgangsmater for anvendelse derav

Info

Publication number
NO20092274L
NO20092274L NO20092274A NO20092274A NO20092274L NO 20092274 L NO20092274 L NO 20092274L NO 20092274 A NO20092274 A NO 20092274A NO 20092274 A NO20092274 A NO 20092274A NO 20092274 L NO20092274 L NO 20092274L
Authority
NO
Norway
Prior art keywords
methods
geldanamycin
compositions
ansamycin
formulations
Prior art date
Application number
NO20092274A
Other languages
English (en)
Norwegian (no)
Inventor
Roger H Pak
Edward B Holson
James L Wright
Louis Grenier
Brian C Austad
James R Porter
John J Lee
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of NO20092274L publication Critical patent/NO20092274L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20092274A 2006-12-12 2009-06-12 Ansamycinformuleringer og fremgangsmater for anvendelse derav NO20092274L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87434906P 2006-12-12 2006-12-12
US91447707P 2007-04-27 2007-04-27
US93991307P 2007-05-24 2007-05-24
PCT/US2007/025317 WO2008073424A2 (en) 2006-12-12 2007-12-11 Ansamycin formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20092274L true NO20092274L (no) 2009-08-25

Family

ID=39410222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092274A NO20092274L (no) 2006-12-12 2009-06-12 Ansamycinformuleringer og fremgangsmater for anvendelse derav

Country Status (14)

Country Link
US (3) US7947670B2 (pt)
EP (1) EP2126548A2 (pt)
JP (1) JP2010512397A (pt)
KR (1) KR20090098982A (pt)
AR (1) AR064304A1 (pt)
AU (1) AU2007332727A1 (pt)
BR (1) BRPI0720277A2 (pt)
CA (1) CA2672537A1 (pt)
CL (1) CL2007003604A1 (pt)
MX (1) MX2009006166A (pt)
NO (1) NO20092274L (pt)
PE (1) PE20081506A1 (pt)
TW (1) TW200833666A (pt)
WO (1) WO2008073424A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545968C (en) * 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20070249827A1 (en) * 2004-06-02 2007-10-25 Sandoz Ag Meropenem Intermediatein in Crystalling Form
EA018698B1 (ru) * 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
EP2404911A1 (en) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
US8426396B2 (en) * 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
ES2347619B1 (es) * 2008-05-13 2011-09-15 Consejo Superior De Investigaciones Cientificas (Csic) (50%) Procedimiento para diseñar una terapia individual antitumoral basado en la deteccion de los niveles de proteina hsp90, el uso de inhibidores de la proteina hsp90 para la elaboracion de composiciones farmaceuticas, las composiciones asi obtenidas y sus aplicaciones.
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
EP2348845A4 (en) * 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
US20110263701A1 (en) * 2010-04-21 2011-10-27 Sigal Blau Gabapentin enacarbil compositions
KR20130101524A (ko) * 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
JP2017110205A (ja) * 2015-12-11 2017-06-22 日本合成化学工業株式会社 結晶成長抑制剤
CN110381945A (zh) * 2017-02-10 2019-10-25 阿尔图姆制药股份有限公司 口服给予的镓（iii）配合物的组合物
WO2018200534A1 (en) * 2017-04-24 2018-11-01 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
IL326637A (en) * 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
GB2581154B (en) * 2019-02-05 2022-09-28 Colvistec Ag Amorphous pharmaceutical compositions
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
HU9401936D0 (en) 1992-01-06 1994-09-28 Pfizer Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
EP0706516A1 (en) * 1993-06-29 1996-04-17 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6051607A (en) 1998-07-02 2000-04-18 Micro Therapeutics, Inc. Vascular embolizing compositions comprising ethyl lactate and methods for their use
EP1098666B1 (en) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6188221B1 (en) 1998-08-07 2001-02-13 Van De Kop Franz Method and apparatus for transmitting electromagnetic waves and analyzing returns to locate underground fluid deposits
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
CA2356959C (en) 1998-12-22 2009-03-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
ATE445673T1 (de) 1999-07-09 2009-10-15 Basf Se Verfahren zur herstellung von pigmenten mit verbesserten coloristischen eigenschaften
SE9904382D0 (sv) * 1999-12-02 1999-12-02 Siemens Elema Ab High Frequency Oscillation Patient Ventilator System
JP2004500358A (ja) 1999-12-08 2004-01-08 ファルマシア　コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
AR028253A1 (es) 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20050203612A1 (en) 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20040148232A1 (en) * 2001-01-22 2004-07-29 Osamu Fushimi Electronic catalog aggregation apparatus for realizing fast and efficient electronic catalog system
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2450762A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
JP2003006555A (ja) 2001-06-25 2003-01-10 Nova:Kk コンテンツ配信方法、シナリオデータ、記録媒体およびシナリオデータ生成方法
JP4032216B2 (ja) 2001-07-12 2008-01-16 ソニー株式会社 光学多層構造体およびその製造方法、並びに光スイッチング素子および画像表示装置
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
EP1420747A4 (en) 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE
JP2005504086A (ja) * 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
US7465718B2 (en) 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
WO2003086381A1 (en) 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
CA2518836A1 (en) 2003-03-13 2004-09-30 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20060024357A1 (en) 2004-05-12 2006-02-02 Medivas, Llc Wound healing polymer compositions and methods for use thereof
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20070148232A1 (en) 2003-12-31 2007-06-28 Pfizer Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers
JP2007530596A (ja) 2004-03-26 2007-11-01 バン アンデル リサーチ インスティチュート ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する
US20050256097A1 (en) 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7179708B2 (en) * 2004-07-14 2007-02-20 Chung Yuan Christian University Process for fabricating non-volatile memory by tilt-angle ion implantation
WO2006034147A2 (en) 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
BRPI0517268A (pt) * 2004-11-02 2008-10-07 Conforma Therapeutics Corp método para tratar uma forma de leucemia linfocìtica crÈnica
EP3345631A1 (en) 2005-02-18 2018-07-11 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
JP2008531708A (ja) 2005-02-28 2008-08-14 コーザン バイオサイエンシス インコーポレイテッド １７−アリルアミノ−１７−デメトキシゲルダナマイシンを含有する医薬製剤
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
EP1871361A2 (en) 2005-04-07 2008-01-02 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
CA2604473A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
MX2007013499A (es) 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
EP1906950A4 (en) 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
KR20080027896A (ko) 2005-06-29 2008-03-28 교와 핫꼬 고교 가부시끼가이샤 벤제노이드 안사마이신 유도체
EP1909763A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones of enhanced bioavailability
WO2007059116A2 (en) 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof
US20090042847A1 (en) 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
CN101360492A (zh) 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
US20070167422A1 (en) 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin

Also Published As

Publication number Publication date
CA2672537A1 (en) 2008-06-19
WO2008073424A3 (en) 2008-07-31
PE20081506A1 (es) 2008-12-09
AR064304A1 (es) 2009-03-25
US7947670B2 (en) 2011-05-24
WO2008073424A2 (en) 2008-06-19
WO2008073424A9 (en) 2008-10-02
CL2007003604A1 (es) 2009-01-23
MX2009006166A (es) 2009-08-26
US20090069281A1 (en) 2009-03-12
AU2007332727A1 (en) 2008-06-19
US8357676B2 (en) 2013-01-22
US20080221077A1 (en) 2008-09-11
US20090062528A1 (en) 2009-03-05
KR20090098982A (ko) 2009-09-18
TW200833666A (en) 2008-08-16
BRPI0720277A2 (pt) 2014-01-28
EP2126548A2 (en) 2009-12-02
JP2010512397A (ja) 2010-04-22
US8283343B2 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
TW200833666A (en) Ansamycin formulations and methods of use thereof
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2009004189A (es) Derivados que contienen sulfamoilo y sus usos.
WO2006138660A3 (en) Sphingosine kinase inhibitors
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
SG162804A1 (en) Pyrazole based lxr modulators
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
WO2006066913A3 (en) Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
GB0222514D0 (en) Organic compounds
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20071314L (no) Peptidiske vasopressinreseptoragonister
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
WO2003072572A8 (en) Beta3-adrenergic receptor agonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application